论文部分内容阅读
目的 :探讨常规血液透析 (CHD)和持续性不卧床腹膜透析 (CAPD)对血清 β2 -微球蛋白 (β2 -MG)的清除作用。方法 :4 5例尿毒症患者分为两组 ,CHD组 30例用FreseniusF6聚风膜透析器 ,每周血液透析治疗 10h ,疗程为 8个月～ 3年 :CAPD组 15例 ,用O型管 (O -Set)和腹膜透析液每日 8升作持续性不卧床腹膜透析治疗 ,疗程为 6个月～ 3年。观察两组患者治疗前后 β2 -MG的变化及血压控制情况。结果 :CHD组透析后 β2-MG较透前增加 (16 1.4 0± 72 .11) % ,CAPD组透析后 β2 -MG较透析前下降 (32 .30 %± 12 .78% ) ;CAPD组血压控制较好 ,两组比较有显著统计学差异 (P <0 .0 5 )。结论 :CAPD对 β2 -MG的清除明显优于CHD ,透析前合并严重高血压的尿毒症患者以选择CAPD治疗较佳。
Objective: To investigate the clearance effect of routine hemodialysis (CHD) and continuous ambulatory peritoneal dialysis (CAPD) on serum β2-microglobulin (β2-MG). Methods: Forty-five patients with uremia were divided into two groups. Thirty patients in CHD group were treated with Fresenius F6 polyfiltration dialyzer for hemodialysis every week for 10 hours. The course of treatment was 8 months to 3 years. Fifteen patients in CAPD group were treated with O-tube (O -Set) and peritoneal dialysis fluid daily 8 liters of continuous ambulatory peritoneal dialysis treatment, treatment of 6 months to 3 years. The changes of β2-MG and the control of blood pressure before and after treatment in both groups were observed. Results: β2-MG increased (16.4 ± 0.11)% after dialysis in CHD group and β2-MG decreased in CAPD group (32.3% ± 12.78% Control is better, there was a significant statistical difference between the two groups (P <0.05). CONCLUSION: The clearance of β2-MG by CAPD is obviously better than that of CHD. Patients with uremia before dialysis should be treated with CAPD.